<DOC>
	<DOCNO>NCT00228566</DOCNO>
	<brief_summary>The purpose study assess patient report outcomes armodafinil treatment term improvement sleepiness , satisfaction treatment , impact ability engage life activity ( ie , daily work family and/or social activity ) , effect fatigue . Clinician rating patient response armodafinil treatment also assess .</brief_summary>
	<brief_title>Study Assess Patient Reported Outcomes With Armodafinil Treatment Excessive Sleepiness Adults With Narcolepsy Obstructive Sleep Apnea/Hypopnea Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<mesh_term>Narcolepsy</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<criteria>Written inform consent obtain . The patient man woman age 18 65 year age ( inclusive ) Englishspeaking . The patient excessive sleepiness associate diagnosis narcolepsy Obstructive Sleep Apnea/Hypopnea Syndrome ( OSAHS ) accord International Classification Sleep Disorders ( ICSD ) criterion . For OSAHS , patient must regular nasal continuous positive airway pressure ( nCPAP ) therapy user ( usage least 4 hours/night least 70 % night ) , must document adequate education intervention effort encourage nCPAP therapy use , patient 's nCPAP therapy regimen must stable least 4 week prior study entry , patient 's nCPAP therapy must effective opinion investigator . The patient good health determine medical psychiatric history , clinical laboratory test , vital sign measurement , electrocardiography ( ECG ) , physical examination , urine drug screen ( UDS ) screening . If currently receive therapy excessive sleepiness associate sleep disorder , patient dissatisfy efficacy and/or safety current therapy ( i.e. , pharmacologic , nap , bright light therapy ) , take , excessive sleepiness associate sleep disorder . The patient Clinical Global Impression Severity Illness ( CGIS ) rating baseline 4 ( i.e. , least moderately ill ) . Women childbearing potential ( surgically sterile 2 year postmenopausal ) must use medically accept method contraception must agree continue use method duration study 30 day participation study . Acceptable method contraception include abstinence , barrier method spermicide , steroidal contraceptive ( oral , transdermal , implanted , inject ) conjunction barrier method , intrauterine device ( IUD ) . The patient must willing able comply study procedure restriction , include completion selfrating scale , willing return study center visit specify protocol . The patient may prescribe pharmacologic therapy excessive sleepiness associate sleep disorder ; however , must undergo washout period least 7 day prior baseline visit . Patients exclude participate study follow criterion meet : The patient treat untreated clinically significant uncontrolled medical psychiatric condition . The patient probable diagnosis current sleep disorder primary diagnosis narcolepsy , OSAHS , etiology complaint excessive sleepiness . The patient consumes caffeine include coffee , tea and/or caffeinecontaining beverage food average 600 mg caffeine/day within 1 week start study drug administration . The patient medically unexplainable positive UDS screen visit . The patient clinically significant deviation normal clinical laboratory test result , vital sign value , physical examination finding observe screen visit . The patient use investigational drug within 30 day 5 halflives ( whichever longer ) study drug administration . The patient use prescription drug disallow protocol within 7 day baseline visit . The patient know suspected hypersensitivity armodafinil compound present study drug relate compound . The patient pregnant lactating . ( Any patient become pregnant study withdrawn study ) . The patient disorder ( include gastrointestinal surgery ) may interfere drug absorption , distribution , metabolism , excretion . The patient history alcohol , narcotic , drug abuse define Diagnostic Statistical Manual Mental Disorders American Psychiatric Association , 4th Edition ( DSMIV ) within past 5 year . The patient history repeat therapeutic failure therapy excessive sleepiness . The patient previously participate clinical study armodafinil .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>